Research programme: tumour growth factor inhibitors - Apoxis

Drug Profile

Research programme: tumour growth factor inhibitors - Apoxis

Alternative Names: APRIL inhibitors

Latest Information Update: 23 Nov 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Apoxis
  • Developer Biogen Idec
  • Class
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 17 Nov 2003 IDEC Pharmaceuticals has merged with Biogen to form Biogen Idec
  • 02 Jul 2003 Preclinical trials in Cancer in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top